The muscle you keep.

The scale is the wrong scoreboard

Semaglutide and tirzepatide are the most effective weight-loss drugs ever brought to market, and there is no honest way to discuss metabolic medicine in 2026 without offering them. But the number on the bathroom scale is a poor description of what these drugs are actually doing to your body. Total weight is the sum of fat mass and lean mass — muscle, bone, organ, and water — and GLP-1 receptor agonists pull from both piles. The clinics advertising "lose 20% of your body weight" are quoting a number that includes muscle they are not telling you you're going to lose.

What the 2026 body-composition data actually shows

Across the major trials and now in large real-world body-composition datasets, a consistent and uncomfortable pattern has emerged: a meaningful share of the weight lost on GLP-1 therapy is lean body mass. Depending on the population and the rate of loss, lean mass has accounted for roughly a quarter to a third of total weight lost — and in sedentary patients with low protein intake, more. This isn't a fringe finding; it's the expected physiology of rapid weight loss without a deliberate muscle-preservation strategy layered on top.

A 2026 real-world analysis using body-composition digital phenotyping sharpened the picture between the two leading agents. In routine care, tirzepatide drove greater lean-mass loss than semaglutide at every measured interval — an excess lean-mass deficit on the order of one to two percent more at 3, 6, 9, and 12 months. The likely reason is mechanical, not mysterious: tirzepatide produces larger total weight loss, and larger, faster weight loss tends to take more muscle with it unless something is done to protect it. The corollary is the hopeful part — the coupling between weight loss and muscle loss is weak, which means muscle-preserving weight loss is an achievable goal, not an inherent trade-off.

Why losing muscle while losing weight is a bad trade

Muscle is not cosmetic tissue. It is the body's largest site of glucose disposal, a primary driver of resting metabolic rate, and the single best-defended buffer against frailty as you age. Lose fat and keep muscle, and you become metabolically healthier, stronger, and harder to re-fatten. Lose fat and muscle, and you lower the very metabolic rate that was keeping the weight off — which is a large part of why people who stop these drugs without a plan regain weight, and often regain it as fat, leaving them with a worse body composition than they started with. The risk is highest in exactly the patients these drugs are most marketed to: older adults and post-menopausal women, who have the least muscle to spare.

The protocol that protects it

Muscle preservation during GLP-1 therapy is not a mystery drug — it's a managed protocol. The levers are well established, and they are the levers a physician-led program actually pulls:

• Protein, deliberately dosed. Appetite suppression is the whole point of the drug, which means patients eat far less without trying — and protein is the first thing to fall. We set an explicit daily protein target (roughly 1.2–1.6 g/kg, individualized) and track it, because hitting it on a suppressed appetite requires planning, not willpower.
• Resistance training from day one. The data are unambiguous: patients who strength-train through GLP-1 therapy retain far more lean mass. We prescribe it as part of the protocol, not as a suggestion — starting the week the drug starts, not after the weight is gone.
• The GH-axis layer where indicated. This is where Limitless differs from a prescription-only mill. Tesamorelin and the broader growth-hormone-axis tools we already use for body composition are anti-catabolic by design — they bias the body toward preserving and building lean tissue while fat comes off. This is not a hopeful inference: a 2026 peer-reviewed pooled meta-analysis of randomized trials (PubMed 41545261) confirms tesamorelin produces visceral-selective fat loss with a significant gain in lean body mass — the exact opposite of the GLP-1 lean-mass cost described above, which is why the two are increasingly used together rather than as substitutes. Used appropriately, the GH-axis layer turns a fat-and-muscle loss curve into a fat-preferential one. (We prescribe these on their own evidence and with honest framing — see our read of the 2026 meta-analysis and the tesamorelin GH-axis review.)
• Hormone status corrected first. A hypogonadal man or an estrogen-depleted woman will lose muscle faster on any weight-loss intervention. We check and correct the endocrine baseline before and during, not as an afterthought.
• Dose titrated to the right rate of loss. Faster is not better. We titrate to a rate that the muscle-preservation protocol can keep pace with, rather than chasing the biggest scale number the drug can deliver.
• Body composition measured, not just weight. If you don't measure lean mass, you are flying blind on the only question that matters. We track composition over time so the protocol can be adjusted to what your body is actually doing.

Semaglutide vs tirzepatide — through the muscle lens

The point of the table is not to crown a winner. It's that the drug is one variable and the protocol is the other — and the protocol is the variable a physician controls. A patient on tirzepatide with protein, resistance training, and a GH-axis layer will keep more muscle than a patient on semaglutide with none of that.